Canary's Litecoin ETF Takes Big Step Toward Nasdaq Listing
Nasdaq moves forward with Canary Capital's Litecoin fund bid through crucial regulatory filing, signaling a potential third spot crypto ETF.
Nasdaq moves forward with Canary Capital's Litecoin fund bid through crucial regulatory filing, signaling a potential third spot crypto ETF.
American Express has agreed to pay more than $138 million to resolve a wire fraud investigation related to its sales and marketing practices, federal authorities announced Thursday. The New York-based financial giant provided inaccurate tax advice to customers and potential customers on wire products primarily marketed at small and mid-size businesses, the U.S. Attorney for the Eastern District of New York's office said. Harry Chavis, a special agent in charge at the Internal Revenue Service’s office in New York, said the company “misled their customers by touting tax breaks that simply didn’t exist."
Wall Street looked set to recover after US banks posted impressive earnings, and inflation data was better than expected.
Stocks failed to continue Wednesday's rally as retail sales and fresh earnings from big banks took focus.
Palantir Technologies (PLTR) stock surged following the re-election of Donald Trump to The White House. Despite CEO Alex Karp’s opposition to Trump, the AI software company seems to have found support due to the close ties between Peter Thiel and soon-to-be vice president JD Vance. However, I’m bearish on the stock, simply because the valuation is very hard to sustain at this moment in time. While the company may experience a wealth of tailwinds when Trump is in office, we don’t know how large t
Wall Street paused, with stocks ending little changed. Strong bank earnings keep rolling in and Trump's Treasury pick fields Senate questions.
Richemont outstripped expectations with a 10 percent jump in revenue during the key holiday quarter, offering hope that luxury's slump might be coming to an end.
American Express (AXP) agreed to pay a total of about $230 million Thursday to settle allegations of past deceptive marketing practices associated with its wire products.
On Wednesday, ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC). NMIBC BCG Unresponsive Papillary Disease: ImmunityBio is preparing to submit a supplemental Biologics License Application (sBLA) in 2025 for its treatment targeting Bacillus Calmette-Guérin (BCG) unresponsive NMIBC in the papillary indication. As published in
(Bloomberg) -- A third straight year of outsize gains in US stocks — a display of strength last seen in the 1990s — leads Bank of America Corp.’s list of potential market surprises for 2025.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyNYC Commuters Get New Way to Dodge Traffic: $95 Helicopter RidesWill Americans Ever Lose Their Taste for Telework?Chicago Agency Pitches $1.5 Billion Plan to Fix Transit WoesChurches, Cinemas — and Moon Artifacts — Top List of E